(Q51019655)

27 March 2018

title

MISCAN: estimating lead-time and over-detection by simulation. (English)

1 reference

27 March 2018

author name string

Draisma G

series ordinal

1

1 reference

27 March 2018

De Koning HJ

series ordinal

2

1 reference

27 March 2018

publication date

1 December 2003

1 reference

27 March 2018

published in

BJU International

1 reference

27 March 2018

volume

92 Suppl 2

1 reference

27 March 2018

page(s)

106-111

1 reference

27 March 2018

Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

International trends in prostate-cancer mortality in the "PSA ERA".

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

Comparative studies of prostate cancer in Japan versus the United States. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

Asymptomatic incidence and duration of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

The MISCAN simulation program for the evaluation of screening for disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

The MISCAN-COLON Simulation Model for the Evaluation of Colorectal Cancer Screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

Lead-time in prostate cancer screening (Finland)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2003.4409X.X

10.1111/J.1464-410X.2003.4409X.X

21 January 2018

Identifiers

DOI

1 reference

27 March 2018

1 reference

27 March 2018